Newsroom
Capricor Therapeutics, Inc. Faces Securities Class Action Lawsuit Deadlines
By KlickAnalytics Data Insights | August 31, 2026 08:02PM ET
Key Points
- Rosen Law Firm reminds Capricor Therapeutics investors of September 28, 2026 lead plaintiff deadline
- Robbins Geller Rudman & Dowd LLP gives Capricor investors until September 28, 2026 to seek lead plaintiff appointment
- Glancy Prongay Wolke & Rotter LLP urges Capricor investors to file lead plaintiff motion by September 28, 2026
- Kaplan Fox & Kilsheimer LLP advises Capricor investors of September 28, 2026 securities class action deadline
- Hagens Berman Sobol Shapiro LLP notifies Capricor investors of September 28, 2026 lead plaintiff deadline amid FDA review extension for Deramiocel
Several law firms are alerting investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming lead plaintiff deadline in a securities class action lawsuit. The Rosen Law Firm is urging individuals who purchased Capricor securities between December 17, 2025, and July 26, 2026, to seek counsel before the important September 28, 2026 deadline. Investors may have the opportunity to lead the shareholder class action lawsuit.
Similarly, Robbins Geller Rudman & Dowd LLP is reminding Capricor investors with substantial losses during the Class Period to take action before the September 28, 2026 deadline to seek appointment as lead plaintiff in the Capicor class action lawsuit. The law firm Glancy Prongay Wolke & Rotter LLP is also urging investors who suffered losses to contact them before the deadline to file a lead plaintiff motion in the class action against Capricor.
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Capricor Therapeutics on behalf of investors who purchased securities during the Class Period. The firm advises investors who have suffered losses to join the case before the September 28, 2026 deadline. Hagens Berman Sobol Shapiro LLP is also notifying investors of the lead plaintiff deadline in the ongoing securities class action, following the FDA's decision to extend the review period for Capricor's Biologics License Application.
In light of alleged misstatements about Deramiocel and the integrity of clinical data, Capricor Therapeutics has faced a significant stock drop, leading to a securities fraud lawsuit. Investors are encouraged to contact law firms such as Bleichmar Fonti & Auld LLP, DJS Law Group, and SBS Law to discuss their rights and potential lead plaintiff appointments in the securities fraud lawsuit against Capricor. The deadline for investors to take action regarding the alleged securities law violations is approaching, and investors are urged to secure counsel before the important deadlines expire.
For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with